There have been few reports on 2
tumor necrosis factor alpha inhibitors,
infliximab and
adalimumab, with respect to patient preference and efficacy in
ulcerative colitis (UC).We used questionnaires to evaluate the preference and reasons for drug choice between
infliximab and
adalimumab in UC patients naive to antitumor
necrosis factor alpha
therapy. We also analyzed the efficacy of
infliximab and
adalimumab prospectively and endoscopically before treatment and at 14 and 54 weeks.Of the 25 UC patients,
infliximab and
adalimumab were chosen by 10 (40%) and 15 (60%), respectively. Patients who favored
infliximab considered "fear of syringes" (7/10, 70%) as the most important influencing factor, whereas patients who favored
adalimumab considered "ease of administration" (10/15, 66.7%) and "time required for
therapy" (10/15, 66.7%) as the most important factors. There were no statistical differences in
remission induction and maintenance between the
infliximab and
adalimumab groups with regard to response, remission, mucosal healing,
steroid-free, and
steroid-free remission rates at weeks 14 and 54.The efficacy of
adalimumab in
remission induction and maintenance was equivalent to that of
infliximab in UC patients naive to antitumor
necrosis factor alpha
therapy in this prospective study, but more patients preferred
adalimumab.